Chinese Volume-Based Procurement Pilot Hits Medtech Stock Prices
The consequences of China’s volume-based, centralized procurement of medical supplies, initiated in 2018, are starting to become clear, according to reports from Omdia.
You may also be interested in...
China is transitioning to an economy driven by innovation and technology, with differential effects on foreign medtechs depending on their place in the value chain and type of innovation. China commentators have been updating the market.
China-specific go-to-market strategies are helping global medtechs access the fast-growing medical device market in China, where localization has become the buzzword for foreign players, writes news and analysis portal Omdia.
The recent COVID-19 lockdown in Shanghai caused widespread disruption locally and an economic slowdown for China. But it did not interrupt the ongoing digitization of health care, the value of which was once again thrown into sharp relief, writes news and analysis portal Omdia.